Invida, Roche partner to commercialize, market primary care products in Korea

As per the agreement, Invida will leverage its capabilities for the management of all of the marketing and sales activities for Roche‘s primary care products, including Xenical, and Roaccutane; as well as products from Roche’s CNS portfolio.

These include Madopar for the treatment of parkinson’s disease and Rivotril for epilepsy and Valium.

Invida CEO John Graham said this will allow Invida and Roche to leverage both companies’ respective strengths to meet the Korean patients’ need for quality pharmaceuticals.

"For Invida, this agreement will provide a roadmap for structuring future partnerships of this nature in Korea and throughout the Asia Pacific region," Graham said.